Floxuridine

Antimetabolite — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Floxuridine is an ofp drug in the Antimetabolite class catalogued in DrugCentral. It was first approved by the FDA in 1970. DrugCentral lists 2 molecular targets, including Tyms and TYMS. Recorded indications include Malignant neoplasm of liver and Primary malignant neoplasm of gastrointestinal tract.

• Approval status: ofp (first approved 1970 by the FDA).
• Drug class: Antimetabolite.
• Molecular targets: Tyms and TYMS (2 listed in DrugCentral).
• Indications: Malignant neoplasm of liver and Primary malignant neoplasm of gastrointestinal tract.
• ATC code: L01BC09 (Pyrimidine analogues).
• Molecular formula: C9H11FN2O5; molecular weight 246.19 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Malignant neoplasm of liver
• Primary malignant neoplasm of gastrointestinal tract

Contraindications (22)

• Acute hemorrhage
• Acute infectious disease
• Anemia
• Bone marrow depression
• Breastfeeding (mother)
• Cholecystitis
• Disease of liver
• Esophagitis
• Fibrosis of bile duct
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Hyperbilirubinemia
• Kidney disease
• Leukopenia
• Liver function tests abnormal
• Myocardial ischemia
• Nutritional disorder
• Persistent vomiting
• Pharyngitis
• Pregnancy, function
• Stomatitis
• Thrombocytopenic disorder

Mechanism & targets

• Established pharmacologic class: Antimetabolite

Molecular targets (2)

Target	Gene	Action	Activity
Thymidylate synthase	Tyms	unknown	IC50 9.40
Thymidylate synthase	TYMS	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1970-12-18	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
L01BC09	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Pyrimidine analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Steatohepatitis	89.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Floxuridine is on its molecule page.

• Molecular formula: C₉H₁₁FN₂O₅
• Molecular weight: 246.19 g/mol
• CAS number: 50-91-9
• InChIKey: ODKNJVUHOIMIIZ-RRKCRQDMSA-N
• PubChem CID: 5790

OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Floxuridine used for?

DrugCentral lists the following indications for Floxuridine: Malignant neoplasm of liver and Primary malignant neoplasm of gastrointestinal tract.

How does Floxuridine work?

Its molecular targets in DrugCentral include Tyms and TYMS (inhibitor).

When was Floxuridine first approved?

Floxuridine was first approved by the FDA in 1970.

What drug class does Floxuridine belong to?

Floxuridine is in the Antimetabolite class.

What is the chemical formula of Floxuridine?

Floxuridine has the molecular formula C9H11FN2O5 and a molecular weight of 246.19 g/mol.

Sources

• DrugCentral drug card 1184 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL917 — compound record and bioactivity
• PubChem CID 5790 — chemical identifiers
• DrugBank DB00322 — drug record
• FDA UNII 039LU44I5M — substance identity
• DailyMed: FDA labels for Floxuridine — current prescribing information (label search)
• UniProt P04818 (TYMS) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.